Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 853 in Adolescent (greater than or equal to 12 to less than 18 Years) and Adult Subjects With Intermittent or Mild to Moderate Persistent Asthma.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 853 in Adolescent (greater than or equal to 12 to less than 18 Years) and Adult Subjects With Intermittent or Mild to Moderate Persistent Asthma.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMG-853 (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors Amgen

Most Recent Events

  • 21 Apr 2011 Status changed from not yet recruiting to discontinued.
  • 05 Aug 2010 Additional trial location [USA] identified as reported by ClinicalTrials.gov.
  • 11 Jun 2010 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top